Imvax Presents Preclinical Data at SITC 2022 Supporting Mechanism of Action and Anti-tumor Activity of its Immunotherapy Platform Across Multiple Tumor Types
– Features of immunogenic cell death linked to the platform’s mechanism of action were associated with immune cell stimulation in lymph nodes –
– Platform found to additionally provide antitumor activity and systemic and durable immunological response in ovarian, liver and bladder cancer models –
PHILADELPHIA, PA (November 10, 2022) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced two poster presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Meeting in Boston, MA, from November 10-12, 2022.
“These new data provide further evidence of the unique mechanism of our immunotherapy platform and its potential applicability in a wide variety of tumor types beyond glioblastoma, where we have compelling clinical data,” said Mark A. Exley, Ph.D., Chief Scientific Officer. “These data support our lead program, IGV-001, which combines personalized, autologous, whole-tumor derived cells with an antisense oligonucleotide in implantable biodiffusion chambers. In addition, these data provide further evidence for our broader portfolio as we work towards filing additional INDs for a range of tumor types with high unmet needs, including endometrial, liver and bladder cancers.”
The first poster presentation on November 10, 2022, reviews a mechanistic evaluation of Imvax’s lead program, IGV-001, which delivered significant improvements in median overall survival in a Phase 1b clinical trial (Andrews, et. al., Clin Can Res 2021). In a murine glioblastoma (GBM) model, indicators of immunogenic cell death (ICD) and activity of cellular stress-related pathways were assessed, in addition to phenotypic analyses of immune cells in draining lymph nodes.
Tumor cells in murine IGV-001 showed significant cell death in vitro and release of ICD markers and higher expression of stress response pathways. Similar levels of cell death were shown in vivo within an implanted biodiffusion chamber, and an increased fraction of several immune cell types, including dendritic cells and multiple T cell subsets, were observed in the draining lymph nodes closest to the chamber. These data suggest a potential mechanism of action of IGV-001 in GBM via ICD stimulation of an antitumor immune response.
The second poster presentation on November 11, 2022, provides evidence for the broad, systemic, and durable antitumor activity of Imvax’s platform. In the ovarian, liver and bladder murine cancer models, treated mice showed statistically significant improvements in post-treatment survival compared to mice in the control groups, as well as reduced tumor size. Additional data from the studies also suggest that efficacy was associated with systemic and durable immunological responses.
About Imvax, Inc.
Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s portfolio includes several programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax’s most advanced program is IGV-001 for the treatment of glioblastoma. Imvax is headquartered in Philadelphia, PA. For additional information, please visit www.imvax.com.
Ten Bridge Communications